The stock may react positively to revenue growth and improved liquidity, but traders should monitor the deteriorating gross margin and increasing net loss as red flags. Future dilution risk is high given the need for additional capital.
Price Chart
Executive Summary
Picard Medical reported 2025 full-year results with 12.5% revenue growth to $4.94 million, driven by product sales of its FDA-approved total artificial heart. Despite improved operating performance, the company widened its net loss to $27.0 million from $21.1 million in 2024, and gross margin deteriorated to -4.1%. Liquidity improved significantly with $11.5 million in cash after raising $27.1 million in financing.
Key Financial Metrics
Key Facts
- Revenue increased 12.5% YoY to $4.94 million in 2025, up from $4.39 million in 2024
- Product revenue was $4.75 million (96% of total), rental revenue $0.19 million
- Gross margin declined to -4.1% from -2.6% in 2024
- Operating loss narrowed slightly to $13.3 million from $13.7 million
- Net loss widened to $27.0 million from $21.1 million in 2024
- Cash, cash equivalents, and restricted cash rose to $11.5 million from $0.1 million at year-end 2024
- Raised $17.4 million in equity and $9.7 million in debt financing during 2025
- Company expects to require additional capital to fund operations
Financial Impact
Revenue up $550K YoY but net loss expanded by $5.9M; gross margin deterioration offsets top-line growth. $27.1M in financing improved liquidity but implies dilution and leverage increase.
Risk Factors
- Continuing negative gross margins may signal unsustainable cost structure
- Widening net loss despite revenue growth raises concerns about path to profitability
- Future capital needs likely to result in further dilution or increased leverage
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3262074 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 3d ago | 8-K | $7.09 | awaiting T+60 | — | $6.70 (−5.50%) |
Oct 22, 2026 5d ago | S-3 | $7.37 | awaiting T+60 | — | $6.70 (+9.09%) |
Oct 6, 2026 21d ago | 8-K | $8.74 | awaiting T+60 | — | $6.70 (+23.34%) |
Jul 27, 2026 13w ago | 8-K | $0.0878 $0.2096 | ▲ +138.72% | ▲ +134.67% | $6.70 (+7530.98%) |
Jul 15, 2026 14w ago | DEFA14A | $0.1600 $0.1896 | ▲ +18.50% | ▲ +14.79% | $6.70 (+4087.50%) |
Jul 8, 2026 15w ago | DEFA14A | $0.1500 $0.0864 | ▼ −42.40% | ▼ −44.89% | $6.70 (+4366.67%) |
Jul 2, 2026 16w ago | 8-K / 425 | $0.1694 | awaiting T+60 | — | $6.70 (+3855.14%) |
Jun 29, 2026 17w ago | 8-K | $0.1559 $0.0910 | ▼ −41.63% | ▼ −45.25% | $6.70 (+4197.63%) |
Jun 2, 2026 21w ago | Press Release | $13.50 | awaiting T+60 | — | $6.70 (−50.37%) |
Jun 2, 2026 21w ago | 8-K | $13.50 | awaiting T+60 | — | $6.70 (+50.37%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers